Lipocine Inc. — Q1 2016 Form 10-Q
Business context and period. Unaudited results cover the three months ended March 31, 2016. Lipocine is a development-stage specialty pharmaceutical company focused on oral drug-delivery products. Its lead candidate, TLANDO, was under FDA review; LPCN 1111 was in Phase 2 and LPCN 1107 in Phase 1.
Financial position and results
| Metric | Q1 2016 / March 31, 2016 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product-sales revenue; no revenue reported for the quarter | No product-sales revenue |
| Research and development expense | $2.67 million | $1.92 million in Q1 2015 |
| General and administrative expense | $4.40 million | $1.06 million in Q1 2015 |
| Net loss | $7.01 million; $0.38 per share | $2.96 million; $0.23 per share in Q1 2015 |
| Operating cash used | $6.51 million | $3.03 million in Q1 2015 |
| Cash and cash equivalents | $14.11 million | $20.01 million at December 31, 2015 |
| Marketable securities | $24.10 million | $24.78 million, including long-term securities, at December 31, 2015 |
| Total assets / liabilities | $38.77 million / $2.99 million | $45.38 million / $3.39 million at December 31, 2015 |
Cash, cash equivalents and marketable securities totaled approximately $38.2 million at quarter-end. The company reported no debt and no credit facility. Gross margin is not meaningful because the company had no product sales. Net loss per share was calculated using 18.25 million weighted-average shares.
Changes versus comparable periods
- Net loss more than doubled from Q1 2015, reflecting higher development and pre-commercialization spending.
- R&D expense increased $755,000. Management attributed the increase primarily to $804,000 in additional TLANDO technical-batch manufacturing costs and $304,000 in personnel costs, partly offset by lower contract research and consulting costs.
- G&A expense increased $3.34 million. Management cited $1.4 million in additional TLANDO business development, market research and pre-commercialization activity, $1.3 million in personnel costs, and other costs including patent litigation and the New Jersey office.
- Operating cash use increased $3.48 million year over year. Cash and cash equivalents declined by $5.89 million during the quarter; investing cash flow was positive largely because securities matured.
Outlook, risks and contingencies
- Management expected the FDA to complete its TLANDO review by the June 28, 2016 PDUFA date, planned a Canadian filing in the second half of 2016, and anticipated Phase 2b top-line results for LPCN 1111 in Q3 2016. It planned to request an FDA end-of-Phase 2 meeting for LPCN 1107 in Q2 2016. These are expectations, not assurances.
- The company estimated approximately $3.7 million in additional TLANDO R&D costs related to FDA review responses and manufacturing launch supplies. It also expected significant manufacturing and commercialization-related spending and increasing operating losses.
- Management believed available capital would fund projected operating requirements for at least 12 months, but noted assumptions could prove incorrect and additional capital may be needed. Future financing may be unavailable or dilutive; the company could have to delay or reduce development or commercialization plans.
- Clarus Therapeutics alleged that TLANDO would infringe its patent in a Delaware lawsuit; Lipocine moved to dismiss. Separately, a patent interference proceeding was pending, with Lipocine designated the senior party. The filing reported no accrued litigation contingency, as management did not consider any contingency probable and estimable.
- Other exposures include operating lease commitments of approximately $730,000 and a perpetual 1% royalty to Abbott on TLANDO net sales, subject to a $1 million cap for the first two calendar years after launch and no cap thereafter.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. The filing identifies no off-balance-sheet arrangements.
Important facts for investors to verify
- Subsequent FDA action on TLANDO, including whether approval was granted by the stated PDUFA date and whether additional studies or requirements were imposed.
- Progress and results for LPCN 1111 and LPCN 1107, and associated development costs and timelines.
- Cash burn, remaining liquid resources, and financing needs relative to planned manufacturing and commercialization spending.
- Status and potential financial or commercial impact of the Clarus patent interference and infringement litigation.
- Share-count reconciliation: the cover reports 18,258,901 shares outstanding as of May 9, 2016, while the balance sheet reports 18,251,191 shares outstanding at March 31, 2016.